Corcept Therapeutics Incorporated
CORT
$71.65
$1.191.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.09% | 34.33% | 47.69% | 39.15% | 38.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.09% | 34.33% | 47.69% | 39.15% | 38.95% |
| Cost of Revenue | 18.08% | 57.49% | 74.29% | 28.59% | 46.83% |
| Gross Profit | 6.93% | 34.00% | 47.33% | 39.29% | 38.85% |
| SG&A Expenses | 61.12% | 76.82% | 62.93% | 54.65% | 15.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.67% | 50.99% | 47.09% | 44.90% | 28.64% |
| Operating Income | -88.61% | -20.23% | 49.46% | 22.00% | 101.98% |
| Income Before Tax | -72.51% | -13.17% | 45.51% | 26.32% | 89.83% |
| Income Tax Expenses | -251.14% | -77.74% | 14.44% | 13.07% | 183.01% |
| Earnings from Continuing Operations | -25.99% | -1.94% | 50.47% | 28.92% | 74.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.99% | -1.94% | 50.47% | 28.92% | 74.83% |
| EBIT | -88.61% | -20.23% | 49.46% | 22.00% | 101.98% |
| EBITDA | -87.71% | -19.89% | 49.37% | 21.01% | 98.89% |
| EPS Basic | -27.19% | -3.55% | 47.81% | 26.95% | 82.73% |
| Normalized Basic EPS | -73.26% | -14.16% | 43.61% | 26.41% | 102.06% |
| EPS Diluted | -32.00% | -8.92% | 46.43% | 28.00% | 78.57% |
| Normalized Diluted EPS | -75.12% | -18.75% | 42.16% | 25.93% | 102.20% |
| Average Basic Shares Outstanding | 1.28% | 1.16% | 1.33% | 1.13% | -4.72% |
| Average Diluted Shares Outstanding | 9.01% | 6.83% | 2.36% | 1.51% | -4.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |